My research expertise spans Molecular Biology, Biochemistry, Cancer Research, Molecular Diagnostics, and Genomics. I hold a BSc in Chemistry from the University of Crete and an MSc in Biology from the Foundation for Research and Technology – Institute of Molecular Biology and Biotechnology (FORTH IMBB). I completed my PhD in Molecular Developmental Biology under the EU Marie Skłodowska-Curie Actions program (University of Stuttgart, CNR, CNRS).

Postdoctoral Research

- Paris, France: Four years of cancer signaling research at INSERM and St. Louis Hospital, focusing on the TP53 tumor suppressor pathway, which yielded significant insights into mechanisms regulating cell cycle control, apoptosis, and oncogenesis.

- Athens, Greece: Four years as Scientific R&D Director at a biotech firm, where I developed innovative molecular clinical diagnostics services, including CE-IVD certified pharmacogenomic (PGx) panels advancing personalized medicine in the frame of translational research.

- Barcelona, Spain: Three years on functional genomics and structural variants with long-read Nanopore sequencing as a Maria Zambrano fellow at the Autonomous University of Barcelona and the Hospital del Mar Research Center (IMIM) at PRBB, contributing to understanding genome architecture and variation.

Current Position: Valencia

Since May 2025, I have been leading a research group at the Department of Biochemistry and Molecular Biology, Faculty of Medicine and Dentistry, University of Valencia. My primary research focuses on the cellular and structural interactions involved in DNA damage sensing and the DNA damage response signaling pathways in cancer. A key aspect of my focus is the role of the p53 tumor suppressor employed as a model to investigate gain-of-function mutations in human cancer. Additionally, the group explores the evolutionary conservation of p53 functions across species, from invertebrates to mammals, to better understand its roles in development and tumor suppression. Currently active collaborations include laboratories within the faculty as well as across Europe, encompassing Spain (PRBB), France (INSERM), the United Kingdom (Oxford University), the Czech Republic (Masaryk Memorial Cancer Institute), Sweden (University of Umeå), and Greece (NHRF).

Keywords: double-stranded DNA brakes, apoptosis, secondary mRNA structures, ATM kinase, MRN complex, H2AX, protein interaction structural interfaces, molecular evolution and human oncogenic pathways, marine invertebrates, elephant, iPSCs, recombinant proteins, protein-protein interactions, sequencing.

Postdoctoral Research

- Paris, France: Four years of cancer signaling research at INSERM and St. Louis Hospital, focusing on the TP53 tumor suppressor pathway, which yielded significant insights into mechanisms regulating cell cycle control, apoptosis, and oncogenesis.

- Athens, Greece: Four years as Scientific R&D Director at a biotech firm, where I developed innovative molecular clinical diagnostics services, including CE-IVD certified pharmacogenomic (PGx) panels advancing personalized medicine in the frame of translational research.

- Barcelona, Spain: Three years on functional genomics and structural variants with long-read Nanopore sequencing as a Maria Zambrano fellow at the Autonomous University of Barcelona and the Hospital del Mar Research Center (IMIM) at PRBB, contributing to understanding genome architecture and variation.

Current Position: Valencia

Since May 2025, I have been leading a research group at the Department of Biochemistry and Molecular Biology, Faculty of Medicine and Dentistry, University of Valencia. My primary research focuses on the cellular and structural interactions involved in DNA damage sensing and the DNA damage response signaling pathways in cancer. A key aspect of my focus is the role of the p53 tumor suppressor employed as a model to investigate gain-of-function mutations in human cancer. Additionally, the group explores the evolutionary conservation of p53 functions across species, from invertebrates to mammals, to better understand its roles in development and tumor suppression. Currently active collaborations include laboratories within the faculty as well as across Europe, encompassing Spain (PRBB), France (INSERM), the United Kingdom (Oxford University), the Czech Republic (Masaryk Memorial Cancer Institute), Sweden (University of Umeå), and Greece (NHRF).

Keywords: double-stranded DNA brakes, apoptosis, secondary mRNA structures, ATM kinase, MRN complex, H2AX, protein interaction structural interfaces, molecular evolution and human oncogenic pathways, marine invertebrates, elephant, iPSCs, recombinant proteins, protein-protein interactions, sequencing.

Marta Moreno Torres holds a Bachelor's degree in Biotechnology at the Polytechnic University of Valencia (UPV), with a research stay at Technische Universität München (TUM) in Munich, Germany. Marta pursued a Master's degree in Biomedical Biotechnology at UPV, with research stays at prestigious institutions such as the Institute of Cellular and Molecular Biology of Plants (IBMCP, UPV-CSIC) and the National University of Ireland (NUIG) in Galway, Ireland.

Marta embarked on an international Ph.D. program at the Université de Fribourg (UniFr) in Fribourg, Switzerland. Afterwards, she obtained a highly competitive 2-year postdoctoral fellowship from the Danish Diabetes Academy. She relocated to Syddansk Universitet (SDU) in Odense, Denmark.

Subsequently, Marta returned to Spain to join the Health Research Institute Hospital La Fe (IISLAFE) in Valencia. There, she assumed a pivotal role with a Juan de la Cierva Incorporación fellowship, specializing on liquid chromatography, mass spectrometry and data analysis from human samples within a hospital environment. Her work aimed to translate her research findings into practical clinical applications within the field of hepatology.

Presently, she holds the prestigious Ramón y Cajal fellowship at the Department of Biochemistry and Molecular Biology within the Faculty of Medicine at the University of Valencia (UV), Spain. Her research is based on a wide set of techniques, including biochemistry, molecular and cellular biology, and cutting-edge mass spectrometry 'omics' technologies.

Research line: Marta's current research focus is centered on the integration of bioanalytical information from multiple platforms, encompassing metabolomics, lipidomics, and miRNA, with clinical data. Leveraging innovative chemometric and machine learning approaches, she endeavors to identify effective biomarkers and phenotypes for personalized therapy surveillance, diagnosis, and prognosis evaluation, particularly in areas such as hepatology and liver transplantation.

Teaching and mentoring: She has supervised four bachelor's and four master's theses and has served as a lecturer and teaching assistant at various esteemed national and international universities. Marta Moreno Torres is accredited as a Ph.D. Lecturer by ANECA and she has actively participated in numerous educational innovation courses in Denmark and Spain, demonstrating her commitment to enhancing the quality of university instruction.